OncoMatch/Clinical Trials/NCT07111832
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Is NCT07111832 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including SHR-A1811 for and SHR-1316 for pd-l1-positive locally recurrent unresectable or metastatic triple-negative breast cancer.
Treatment: SHR-A1811 for · SHR-1316 · Toripalimab · Paclitaxel for — This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
Demographics
Prior therapy
Cannot have received: anti-tumor treatment
Exception: within 4 weeks before the first dose
Have undergone other anti-tumor treatment within 4 weeks before the first dose
Lab requirements
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07111832 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-tumor treatment disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify